Epigenetics: Making the most of methylation
- University Medical Center Utrecht, Netherlands
DNA methylation is a key mechanism used by higher eukaryotes to regulate gene expression. The addition of a methyl group to carbon atom number 5 within cytosine bases in DNA is known to repress the transcription of genes into messenger RNA molecules, thus reducing the production of the proteins coded by these genes. Most methylation occurs at CpG dinucleotides—cytosines that are paired with guanines—and these often cluster together to form CpG islands in the promoter regions of genes. In the late 1990s, it was discovered that transcription was repressed when methyl CpG binding proteins were recruited to methylated CpG islands (Hendrich and Bird, 1998).
Subsequent studies have confirmed that the binding of these proteins throughout the genome is proportional to the density of DNA methylation (Baubec et al., 2013), and have identified additional proteins with a high affinity for methylated CpG sites (reviewed in Defossez and Stancheva, 2011). Moreover, in recent years, other screening approaches based mainly on mass spectrometry have revealed that more proteins bind to methylated DNA than previously thought (Mittler et al., 2009; Bartke et al., 2010; Bartels et al., 2011; Spruijt et al., 2013). Now, in eLife, Heng Zhu and co-workers at the Johns Hopkins University School of Medicine—including Shaohui Hu as first author—use a high-throughput screening method to show that many human transcription factors also interact with genomic DNA sequences containing methylated CpG sites (Hu et al., 2013).
To this end, the Johns Hopkins researchers made use of a published protein microarray consisting of 1,321 transcription factors and 210 co-factors (Hu et al., 2009). Hu et al. incubated the array with 154 distinct human promoter sequences, each of which contained at least one methylated CpG dinucleotide.Their results revealed that 150 (97%) of the 154 methylated human promoter sequences showed specific binding to at least one protein on the microarray. Moreover, of the 1531 proteins, 47 (3%) showed binding to methylated cytosines within the promoters. Most of the proteins bound to methylated DNA in a sequence-dependent manner; however, a minority bound to many different methylated DNA probes, indicating that binding can sometimes occur independent of DNA sequence (Figure 1).
Figure 1
Some human transcription factors can bind to both methylated and non-methylated DNA sequences. Hu et al. examined the ability of 17 human transcription factors to bind to 150 different DNA motifs containing methylated or non-methylated CpG islands. Each row represents one transcription factor. For each motif, some transcription factors bound only to the methylated version (red), some to only the non-methylated version (blue); some to both methylated and non-methylated versions (green), and some to neither (grey). From Figure 2a in Hu et al., 2013.
A number of transcription factors, including KLF4—a recently identified methyl-CpG binding protein (Spruijt et al., 2013)—interacted with methylated sequences that did not resemble their known consensus DNA binding motifs. Using a technique based on electrophoresis, Hu et al. showed that KLF4 binds methylated and non-methylated DNA in a non-competitive manner: this suggests that different domains of the protein may be responsible for each type of binding, which they duly confirmed using molecular modeling and mutagenesis studies.
The Johns Hopkins researchers then mined published ChIP-sequencing data from stem cells to identify the target DNA sequences of KLF4, and compared these with data on genome-wide DNA methylation. Strikingly, KLF4 binding appears to be bimodal in nature throughout the genome, with 38% of KLF4 binding sites showing less than 20% methylation, and 48% showing methylation levels over 80%. Finally, Hu et al. used ChIP-bisulfite sequencing, which makes it possible to determine the methylation status of each cytosine within a target DNA sequence, to confirm that KLF4 also binds to both methylated and non-methylated DNA in vivo.
Hu et al. only profiled a small fraction of the complete human methylome for interactions with transcription factors; further proteins capable of binding genomic methyl CpG sequences surely await identification. The same holds true for interactions with methylated non-CpG sequences such as methyl-CpA (cytosine adjacent to adenine), which are fairly abundant in embryonic stem cells (Ramsahoye et al., 2000; Lister et al., 2009). To determine the physiological relevance of these interactions, it will be important to deduce the affinity with which proteins bind these sequences compared to their known targets; initial experiments along these lines are presented in the current eLife paper. Furthermore, recent evidence suggests that non-methylated CpG islands recruit activator proteins, many of which contain a CXXC motif (reviewed in Long et al., 2013). The transcription factor microarray approach used by the Johns Hopkins team, combined with quantitative mass spectrometry-based technology (Spruijt et al., 2013), could thus be used to identify the complete cellular complement of proteins that bind specifically to non-methylated CpG islands.
Finally, this study and other recently published papers force us to reconsider the mechanism(s) via which CpG methylation regulates transcription. Although DNA methylation is generally considered to be a repressive epigenetic modification, experiments presented by Hu et al. suggest that in some cases, methylation of a given promoter sequence can result in activation of transcription. Moreover, other work has revealed a temporal uncoupling of DNA methylation and transcriptional repression during Xenopus embryogenesis (Bogdanovic et al., 2011). Further experiments are therefore required to determine whether the functional readout of CpG methylation is affected by the repertoire and abundance of different DNA methylation ‘readers’ acting at any given time in a cell or a developing organism.
References
-
Biological functions of methyl-CpG-binding proteinsProg Mol Biol Transi Sci 101:377–398.https://doi.org/10.1016/B978-0-12-387685-0.00012-3
-
Identification and characterization of a family of mammalian methyl-CpG binding proteinsMol Cell Biol 18:6538–6547.
-
ZF-CxxC domain-containing proteins, CpG islands and the chromatin connectionBiochem Soc trans 41:727–740.https://doi.org/10.1042/BST20130028
Article and author information
Author details
Publication history
- Version of Record published: September 3, 2013 (version 1)
Copyright
© 2013, Vermeulen
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 518
- views
-
- 56
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Epigenetics: Making the most of methylation
eLife 2:e01387.
https://doi.org/10.7554/eLife.01387
Further reading
-
- Biochemistry and Chemical Biology
- Neuroscience
Amyloid β (Aβ) peptides accumulating in the brain are proposed to trigger Alzheimer’s disease (AD). However, molecular cascades underlying their toxicity are poorly defined. Here, we explored a novel hypothesis for Aβ42 toxicity that arises from its proven affinity for γ-secretases. We hypothesized that the reported increases in Aβ42, particularly in the endolysosomal compartment, promote the establishment of a product feedback inhibitory mechanism on γ-secretases, and thereby impair downstream signaling events. We conducted kinetic analyses of γ-secretase activity in cell-free systems in the presence of Aβ, as well as cell-based and ex vivo assays in neuronal cell lines, neurons, and brain synaptosomes to assess the impact of Aβ on γ-secretases. We show that human Aβ42 peptides, but neither murine Aβ42 nor human Aβ17–42 (p3), inhibit γ-secretases and trigger accumulation of unprocessed substrates in neurons, including C-terminal fragments (CTFs) of APP, p75, and pan-cadherin. Moreover, Aβ42 treatment dysregulated cellular homeostasis, as shown by the induction of p75-dependent neuronal death in two distinct cellular systems. Our findings raise the possibility that pathological elevations in Aβ42 contribute to cellular toxicity via the γ-secretase inhibition, and provide a novel conceptual framework to address Aβ toxicity in the context of γ-secretase-dependent homeostatic signaling.
-
- Biochemistry and Chemical Biology
- Plant Biology
Transmembrane signaling by plant receptor kinases (RKs) has long been thought to involve reciprocal trans-phosphorylation of their intracellular kinase domains. The fact that many of these are pseudokinase domains, however, suggests that additional mechanisms must govern RK signaling activation. Non-catalytic signaling mechanisms of protein kinase domains have been described in metazoans, but information is scarce for plants. Recently, a non-catalytic function was reported for the leucine-rich repeat (LRR)-RK subfamily XIIa member EFR (elongation factor Tu receptor) and phosphorylation-dependent conformational changes were proposed to regulate signaling of RKs with non-RD kinase domains. Here, using EFR as a model, we describe a non-catalytic activation mechanism for LRR-RKs with non-RD kinase domains. EFR is an active kinase, but a kinase-dead variant retains the ability to enhance catalytic activity of its co-receptor kinase BAK1/SERK3 (brassinosteroid insensitive 1-associated kinase 1/somatic embryogenesis receptor kinase 3). Applying hydrogen-deuterium exchange mass spectrometry (HDX-MS) analysis and designing homology-based intragenic suppressor mutations, we provide evidence that the EFR kinase domain must adopt its active conformation in order to activate BAK1 allosterically, likely by supporting αC-helix positioning in BAK1. Our results suggest a conformational toggle model for signaling, in which BAK1 first phosphorylates EFR in the activation loop to stabilize its active conformation, allowing EFR in turn to allosterically activate BAK1.
